Roquefort Investments PLC Cash Flow Conversion Efficiency
Roquefort Investments PLC cash flow conversion efficiency. Based on the latest financial reports, Roquefort Investments PLC (ROQ) has a cash flow conversion efficiency ratio of -0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-329.55K ≈ $-40.10 USD) by net assets (GBX4.75 Million ≈ $578.29 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Roquefort Investments PLC (2021–2024)
Cash flow conversion efficiency of Roquefort Investments PLC from 2021 to 2024. This chart illustrates how Roquefort Investments PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Roquefort Investments PLC stock quote for real-time trading data and today's change.
Roquefort Investments PLC Cash Flow Conversion Ratio Explained
Roquefort Investments PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Roquefort Investments PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roquefort Investments PLC ranked by their cash flow conversion efficiency. Also see market cap of Roquefort Investments PLC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Symphony Environmental Technologies plc
LSE:SYM
|
0.236x |
|
Checkit PLC
LSE:CKT
|
-0.132x |
|
Adventure Box Technology AB
ST:ADVBOX
|
0.624x |
|
Pennant International Group plc
LSE:PEN
|
0.136x |
|
JDC Group AG
XETRA:JDC
|
0.053x |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
0.024x |
|
Trustco Group Holdings
JSE:TTO
|
-0.004x |
|
Northern Bear Plc
LSE:NTBR
|
0.123x |
Annual Cash Flow Conversion Efficiency for Roquefort Investments PLC (2021–2024)
The table below shows the annual cash flow conversion efficiency of Roquefort Investments PLC from 2021 to 2024. Review Roquefort Investments PLC free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX4.89 Million ≈ $594.85 |
GBX-783.73K ≈ $-95.36 |
-0.160x | +49.14% |
| 2023-12-31 | GBX5.50 Million ≈ $669.14 |
GBX-1.73 Million ≈ $-210.92 |
-0.315x | -44.00% |
| 2022-12-31 | GBX7.21 Million ≈ $876.84 |
GBX-1.58 Million ≈ $-191.93 |
-0.219x | +65.93% |
| 2021-12-31 | GBX4.08 Million ≈ $496.74 |
GBX-2.62 Million ≈ $-319.15 |
-0.642x | -- |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more